Dianthus Therapeutics (DNTH) is a clinical-stage biotech company that develops antibody complement therapeutics. CEO Marino Garcia joins Oliver Renick to discuss DNTH. DNTH completed a merger with Magenta Therapeutics and began trading on the NASDAQ under the ticker “DNTH.” DNTH announced positive top-line phase 1 data for DNTH103 treatment. Tune in to find out more about the stock market today.
15 Sep 2023
Market On Close
24 Oct 2023
The Watch List
21 Sep 2023
Market On Close
09 Nov 2023
The Watch List
02 Oct 2023
Trading 360
09 Nov 2023
Market On Close
30 Nov 2023